Human stem cell-based cell replacement therapy for Parkinson’s disease:Enhancing the survival of postmitotic dopamine neuron grafts  

作　　者：Tae Wan Kim 

机构地区：[1]Department of Interdisciplinary Engineering,DGIST,Daegu,Republic of Korea

出　　处：《Neural Regeneration Research》2026年第2期689-690,共2页中国神经再生研究(英文版)

基　　金：supported by the DGIST start-up funds from the Ministry of Science and ICT(2024010330);a National Research Foundation of Korea(NRF)grant funded by the Korea Government(MSIT)(No.RS-2024-00351442)(to TWK).

摘　　要：Parkinson’s disease(PD)is the second most common neurodegenerative disorder.The progressive degeneration of dopamine(DA)producing neurons in the midbrain is the pathological hallmark,which leads to debilitating motor symptoms,including tremors,rigidity,and bradykinesia.Drug treatments,such as levodopa,provide symptomatic relief.However,they do not halt disease progression,and their effectiveness diminishes over time(reviewed in Poewe et al.,2017).

关 键 词：neuronal survival cell replacement therapy dopamine neurons human stem cells bradykinesiadrug treatmentssuch Parkinsons disease neurodegenerative disorderthe parkinson s disease pd 

分 类 号：R742.3[医药卫生—神经病学与精神病学]